Perspective Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
AMEX
Perspective Therapeutics, a radiopharmaceutical developer, reported significant R&D investment and clinical progress for its alpha-particle therapies, alongside a recent $175 million capital raise, despite continued net losses.
AMEX
10-K/A: Perspective Therapeutics Amends 10-K to Include Signed Audit Report; Provides Business Update
Perspective Therapeutics files an amendment to its 2024 Form 10-K solely to include the signed audit report from WithumSmith+Brown, PC, while also providing a comprehensive business update.
AMEX
Perspective Therapeutics highlights clinical progress, manufacturing expansion, and strategic agreements in its 2024 annual report, positioning itself for future growth in the radiopharmaceutical market.
AMEX
Perspective Therapeutics details its strategy for developing targeted alpha therapies for cancer, leveraging its proprietary platform and recent acquisitions.